Evidence map›Paper›PMID 36300903›Full record

ReviewPain practice : the official journal of World Institute of Pain2023

Gabapentin-Friend or foe?

Marc Russo, Brett Graham, Danielle M Santarelli

Registry-linked trialOpen access · hybridAbstract readReview
In one paragraph

Review in Pain practice : the official journal of World Institute of Pain, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06798662 (Multimodal Nerve Block and Pulse Radiofrequency for Acute Herpes Zoster Pain), which is not on this map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06798662 nanot yet recruitingnot on this mapstarted 2025, after this paper: background citation

Multimodal Nerve Block and Pulse Radiofrequency for Acute Herpes Zoster Pain: a Prospective, Randomized, Controlled, Triple-blind Trial

TypeinterventionalSponsorXiaguang DuanRan2025 to 2025Enrolled120ConditionsHerpes Zoster (HZ)ArmsUltrasound-Guided Pulsed Radiofrequency (PRF), Intercostal nerve block (2% ropivacaine or 133 mg of liposomal bupivacaine), Paravertebral (PVB) Block (2% ropivacaine or 133 mg of liposomal bupivacaine), Rhomboid Intercostal and Subserratus Plane (RISS) Block (2% ropivacaine or 133 mg of liposomal bupivacaine), Drug (famciclovir and gabapentin)
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Gabapentin: Clinical Use and Pharmacokinetics in Dogs, Cats, and Horses.Animals : an open access journal from MDPI · 2023
    Review
  20. Principles of nociceptive coding in the anterior cingulate cortex.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Marc RussoHunter Pain Specialists, Broadmeadow, New South Wales, Australia.ORCID 0000-0001-7364-9917
Brett GrahamSchool of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, New South Wales, Australia.
Danielle M SantarelliGenesis Research Services, Broadmeadow, New South Wales, Australia.
Hunter Genetics · AUUniversity of Newcastle Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGabapentin is a recommended first-line agent for treating neuropathic pain; however, its efficacy rate is reportedly low, and the risk of adverse events is high. A plausible explanation for this lies with its wide range of actions, the entirety of which have yet to be fully elucidated.

methodsA review of the literature was conducted on gabapentin's known and proposed analgesic mechanisms of action, as well as potentially opposing or detrimental actions.

resultsGabapentin's classical analgesic mechanisms involve direct attenuation of excitatory neurotransmission in the spinal cord via inhibition of neuronal ion channels, while indirect mechanisms include descending inhibition and block of injury-evoked synaptogenesis. Glial effects have also been reported; however, whether they are neuroprotective or detrimental is unknown. Furthermore, data from animal models do not reflect clinical outcomes.

conclusionsGabapentin's clinical use should be reconsidered according to the net effects of its numerous assumed actions, including the tripartite synapse and oligodendrocyte effects. Whether it is doing more harm than good, especially in the scenarios of incomplete or loss of response, warrants consideration when prescribing gabapentin.

Indexed as

Cyclohexanecarboxylic Acidsgamma-Aminobutyric AcidAminesAnalgesicsAnimalsGabapentinAminesAnalgesicsCyclohexanecarboxylic AcidsGabapentingamma-Aminobutyric Acidanalgesiagabapentinglial cellsneuropathic painpharmacologic actions

Identifiers

PMID36300903
PMCPMC10092611
OpenAlexW4307427363

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.